9/4/2013

The European Commission has approved the use of GlaxoSmithKline's Tafinlar, or dabrafenib, for unresectable or metastatic melanoma related to the BRAF V600 variation. The drug won FDA approval in May.

Full Story:
PharmaTimes (U.K.)

Related Summaries